HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Naot, D. Articles by Cornish, J. Search for Related Content PubMed PubMed Citation Articles by Naot, D. Articles by Cornish, J.

Lactoferrin – A Novel Bone Growth Factor

Dorit Naot, PhD; Andrew Grey, MD; Ian R. Reid, MD; Jillian Cornish, PhD; Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand.

Reprint Requests: Dorit Naot, PhD, Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand. Tel: 64-9-373-7599, ext 86258; Fax: 64-9-373-7677; Email: d.naot{at}auckland.ac.nz

Lactoferrin is an iron-binding glycoprotein that belongs to the transferrin family. It is present in breast milk, in epithelial secretions, and in the secondary granules of neutrophils. In healthy subjects lactoferrin circulates at concentrations of 2–7 x 10^–6 g/ml. Lactoferrin is a pleiotropic factor with potent antimicrobial and immunomodulatory activities. Recently, we have shown that lactoferrin can also promote bone growth. At physiological concentrations, lactoferrin potently stimulates the proliferation and differentiation of primary osteoblasts and also acts as a survival factor inhibiting apoptosis induced by serum withdrawal. Lactoferrin also affects osteoclast formation and, in murine bone marrow culture, lactoferrin potently inhibits osteoclastogenesis. In vivo, local injection of lactoferrin above the hemicalvaria of adult mice results in substantial increases in the dynamic histomorphometric indices of bone formation and bone area.

The mitogenic effect of lactoferrin in osteoblast-like cells is mediated mainly through LRP1, a member of the family of low-density lipoprotein receptor-related proteins that are primarily known as endocytic receptors. Using confocal laser scanning microscopy, we demonstrated that fluorescently labeled lactoferrin is endocytosed and can be visualized in the cytoplasm of primary osteoblastic cells. Lactoferrin also induces activation of p42/44 MAPK signaling in primary osteoblasts, but the two pathways seem to operate independently as activation of MAPK signaling, but not endocytosis, is necessary for the mitogenic effect of lactoferrin. We conclude that lactoferrin may have a physiological role in bone growth and healing, and a potential therapeutic role as an anabolic factor in osteoporosis.

Key Words: Lactoferrin • Bone development • Bone remodeling • Bone regeneration • Anabolic agents • LDL-Receptor Related Protein 1

This article has been cited by other articles:

				H. Y. Guo, L. Jiang, S. A. Ibrahim, L. Zhang, H. Zhang, M. Zhang, and F. Z. Ren Orally Administered Lactoferrin Preserves Bone Mass and Microarchitecture in Ovariectomized Rats J. Nutr., May 1, 2009; 139(5): 958 - 964. [Abstract] [Full Text] [PDF]